Format

Send to

Choose Destination
Breast Cancer Res Treat. 2016 Dec;160(3):439-446. doi: 10.1007/s10549-016-4013-7. Epub 2016 Oct 15.

miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.

Author information

1
MTA TTK Lendület Cancer Biomarker Research Group, Magyar Tudósok körútja 2, Budapest, 1117, Hungary.
2
Department of Pediatrics, Semmelweis University, Budapest, Hungary.
3
Oncology Experimental Therapeutics Unit, Humanitas Clinical and Research Institute, Via Manzoni 113, 20089, Rozzano-Milan, Italy.
4
MTA-SE Pediatrics and Nephrology Research Group, Budapest, Hungary.
5
Oncology Experimental Therapeutics Unit, Humanitas Clinical and Research Institute, Via Manzoni 113, 20089, Rozzano-Milan, Italy. libero.santarpia@humanitasresearch.it.
6
MTA TTK Lendület Cancer Biomarker Research Group, Magyar Tudósok körútja 2, Budapest, 1117, Hungary. gyorffy.balazs@ttk.mta.hu.
7
Department of Pediatrics, Semmelweis University, Budapest, Hungary. gyorffy.balazs@ttk.mta.hu.

Abstract

PURPOSE:

The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, we developed an integrated online bioinformatic tool to validate the prognostic relevance of miRNAs in breast cancer.

METHODS:

A database was set up by searching the GEO, EGA, TCGA, and PubMed repositories to identify datasets with published miRNA expression and clinical data. Kaplan-Meier survival analysis was performed to validate the prognostic value of a set of 41 previously published survival-associated miRNAs.

RESULTS:

All together 2178 samples from four independent datasets were integrated into the system including the expression of 1052 distinct human miRNAs. In addition, the web-tool allows for the selection of patients, which can be filtered by receptors status, lymph node involvement, histological grade, and treatments. The complete analysis tool can be accessed online at: www.kmplot.com/mirpower . We used this tool to analyze a large number of deregulated miRNAs associated with breast cancer features and outcome, and confirmed the prognostic value of 26 miRNAs. A significant correlation in three out of four datasets was validated only for miR-29c and miR-101.

CONCLUSIONS:

In summary, we established an integrated platform capable to mine all available miRNA data to perform a survival analysis for the identification and validation of prognostic miRNA markers in breast cancer.

KEYWORDS:

Biomarkers; Breast cancer; Gene expression; MicroRNAs; Prognosis; Survival

PMID:
27744485
DOI:
10.1007/s10549-016-4013-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center